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After its emergence in 2019, COVID-19 has quickly become a leading cause of morbidity and 
mortality in many nations. Furthermore, the emergence of variants of concern has led to fears 
that SARS-CoV-2, the virus responsible for COVID-19, could begin evading vaccine acquired 
immunity. Thus, understanding the factors contributing to severe disease progression is 
critically important to the public health response and the treatment of severely ill COVID-19 
patients. This study examines the role complement protein has in development of severe 
disease in COVID-19 patients. Complement is a group of proteins that play a critical part of the 
innate immune system responsible for immune cell recruitment, bacterial lysis, and 
opsonization of pathogens among many things. To examine the role, complement plays in 
progression of disease severity in COVID-19 patients, a cohort of hospitalized patients was 
selected from volunteers admitted to the University of Pittsburgh Medical Center Presbyterian 
Hospital in Allegheny County, Pennsylvania. Serum from the patients was collected as part of 
routine medical procedures and excess serum was analyzed via ELISA assays to determine the 
level of complement factor proteins during disease progression. Following analysis, it was clear 
that complement factor proteins were significantly elevated in patients with higher body mass 
index scores. Additionally, it was demonstrated that complement factor proteins were 
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positively correlated with the ratio of IgG antibodies and IgA antibodies. Furthermore, it was 
demonstrated that patients with higher ratios of IgG to IgA, and thus higher complement levels, 
had more severe disease compared to those with higher ratios of IgA to IgG. Together this 
suggests that IgA is protective against severe disease by down regulating complement 
activation, and suggesting higher levels of complement activation was a contributor to more 
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Beginning in the waning months of 2019 reports began surfacing in Wuhan, Hubei province 
of a viral pneumonia of unknown etiology caused several people to require mechanical 
ventilation. By January 2020 the genome of the etiological agent had been sequenced, its 
association with the disease confirmed by a research team located in China. The viral genome 
sequence had  over 90% genetic similarity to Severe Acute Respiratory Syndrome Coronavirus 
(SARS-CoV): a respiratory coronavirus which emerged in 2003 and caused over 800 deaths in a 
3-month span as it spread rapidly within Southeast Asia and Canada (Xu, Zhao et al. 2020). 
Cases of the novel coronavirus quickly began to climb within Hubei province in early 2020, 
prompting the central government of China to implement a complete exclusion zone around 
Wuhan and mandatory quarantine of known or suspected cases. By March 11 the WHO had 
declared SARS-CoV-2 a global pandemic, and cases soon began appearing in the United States, 
beginning in Washington state(2021). To date the SARS-CoV-2 pandemic has infected over 200 
million people resulting in more than 4.03 million deaths since its emergence (2021) as of 
August 12, 2021. With current vaccination rates not expected to result in global herd immunity 
until 2024 at the earliest, understanding the host response that is leading to severe disease is 
imperative to create effective preventive measures and treatments to reduce mortality by 






1.1 SARS-CoV-2 and Other Fatal Coronaviruses 
 
Coronaviruses are non-segmented positive sense RNA viruses that are broken into 4 
subfamilies with alpha and beta coronaviruses being the 2 genera contribute to the majority of 
disease in humans. Coronaviruses as a family have been with humans for generations, seldom 
causing severe disease and thus receiving minimal attention compared to other respiratory 
pathogens. Prior to the emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-
CoV) in southern China’s Guangdong province, coronaviruses such as HKU1 and OC43 were 
mainly responsible for easily manageable ‘colds’ during winter months (Cui, Li et al. 2019). The 
2003 SARS-CoV emergence was particularly alarming to the international community as it was 
the first deadly coronavirus in modern times, with a calculated case fatality rate (CFR) across all 
ages of 9.6% as well as the first to efficiently infect the lower respiratory tract leading to acute 
respiratory distress syndrome (ARDS) in many patients (Zhu, Lian et al. 2020). Additionally, 
genetic analysis of SARS-like coronaviruses indicated zoonotic transfer from palm civets was 
likely the cause of initial human infections in the SARS-CoV outbreak of 2003, implicating illegal 
animal trading and wet markets as industries that could cause future fatal coronaviruses to 
emerge (Zhu, Lian et al. 2020). For SARS-CoV-2 however, genomic analysis suggests that SARS-
CoV-2 emerged from bat populations within China though the exact pathway from bat 
populations to humans hasn’t been fully elucidated (Andersen, Rambaut et al. 2020). 
In 2012, 9 years after the emergence of SARS-CoV, a patient in Zarqa, Jordan presented with 
a similar syndrome that led to the identification of Middle East Respiratory Syndrome 
coronavirus (MERS-CoV), another beta-coronavirus. Further investigation suggested that MERS, 
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like SARS-CoV, has a natural reservoir in bats but utilized camels instead of Palm Civets as an 
intermediary species corroborating the coronavirus’s ability to adapt to wide array of fauna to 
make the jump from bats to humans (Zhu, Lian et al. 2020). Interestingly, SARS-CoV became 
known for super-spreading events, where one infected individual transmits the virus to dozens 
of others in a very short period of time. The most famous instance of this occurring in a hotel in 
Hong Kong where an infected man infected several foreign nationals leading to the virus 
spreading to several countries (Shen, Ning et al. 2004) This type of super-spreading event also 
occurred on a flight to Singapore where a single flight attendant infected over 100 passengers 
leading to a significant number of cases in the country (Al-Tawfiq and Rodriguez-Morales 2020). 
Luckily, MERS has only had one such well documented event in South Korea (Al-Tawfiq and 
Rodriguez-Morales 2020) but it has demonstrated an increased mortality rate compared to 
SARS-CoV with a CFR of 34.3%, although its decreased transmissibility (R0 of 0.8-1.3) has 
prevented MERS from spreading rapidly or infecting large population groups the way SARS-CoV 
did (Zhu, Lian et al. 2020).  
Finally, the most recent fatal coronavirus, Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2), emerged from central China’s Hubei province in the waning months of 2019. 
Much like SARS-CoV and MERS-CoV, SARS-CoV-2, has well documented cases of superspreading 
events, a feature that drove infections of both SARS and MERS (Al-Tawfiq and Rodriguez-
Morales 2020). However, compared to SARS-CoV and MERS-CoV, SARS-CoV-2 has proven to be 
less lethal on a per person basis, with a predicted global CFR of 2-3%, though its significantly 
higher transmissibility has caused exponentially higher casualties compared to MERS and SARS-
CoV (Cao, Hiyoshi et al. 2020) . It should be noted that due to the ongoing nature of the 
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pandemic as well as asymptomatic carriers, the true fatality rate is likely significantly lower than 
the calculated CFR. Furthermore, the fatality rate is highly variable across nations, as those with 
higher rates of co-morbidities, or those with decreased healthcare infrastructure have 
significantly higher fatality rates. Overall, SARS-CoV and SARS-CoV-2 share substantial 
similarities to one another, compared to SARS-CoV-2 and MERS-CoV. This is exemplified by the 
genetic similarity of SARS-CoV and SARS-CoV-2 as they share nearly 99% homology between the 
stalk of the spike glycoprotein in each virus (Xu, Zhao et al. 2020).  
In contrast to the other recent coronavirus, the SARS-CoV-2 virus is capable of much more 
effective transmission. The reasons for the increased transmissibility may be related to the 
wide spectrum of clinical presentations ranging from mild cough to acute respiratory distress 
syndrome as well as documented transmission even during asymptomatic and pre-symptomatic 
stages of disease (Furukawa, Brooks et al. 2020). COVID-19 presents with fever in 77% of cases, 
cough in 65% of cases, followed by fatigue in 27% and dyspnea in 21% of cases (Sheleme, 
Bekele et al. 2020). However, in roughly 18% of infected individuals they fail to present with any 
symptoms (Mizumoto, Kagaya et al. 2020).   Overall, the high frequency of asymptomatic cases, 
the ability to transmit virus during the pre-symptomatic stages and early symptomatic stages, 
as well as the increased affinity for cellular receptors, are likely to play a significant role in the 
transmissibility of SARS-CoV-2.   
 
1.2 Current Epidemiology and Intervention Against SARS-CoV-2 
  
SARS-CoV-2 is a respiratory pathogen that is transmitted primarily through airborne and 
droplet spread from an infected individual. After infection, a patient has an average incubation 
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period of 6 days, though this can range anywhere from 2 to 21 days, with the infectious period 
beginning 2 days prior to symptom onset. However, it has also been well documented that 
SARS-CoV-2 has also been spread effectively by asymptomatic carriers, who may be actively 
shedding viral particles for up to 21 days (Hu, Song et al. 2020). On average a person is 
infectious for 8 days post symptom onset, and symptomatic for a similar timeframe. However, 
severe disease progression follows a much longer course with average hospital admission 
around day 8 post symptom onset with the most severe cases reaching 28 days or more post 
symptom onset before disease outcome, tying up hospital resources for a significant amount of 
time on a per patient basis (Wang, Zheng et al. 2021).  
SARS-CoV-2 has been characterized, especially within countries who did not take proactive 
measures, by exponentially propagating outbreaks, caused principally by populations lacking 
any meaningful adaptative immune responses capable to protect against SARS-CoV-2. A direct 
example of the difference proactive measures can make has been demonstrated in the Nordic 
nations in Northern Europe. Sweden took a laissez-faire approach to the pandemic and as a 
result, Sweden faced 3 times the cases per capita than the next closest country in the region, 
Denmark, and had a 5% increase in all-cause mortality over the study period while there was a 
5% and 3% decrease in Norway and Denmark during the same period (Yarmol-Matusiak, 
Cipriano et al. 2021). Recent estimates of R0, or the reproductive rate of the virus, place SARS-
CoV-2 around 3.6 and 6.1, dependent on interventions imposed by regional authorities as well 
as emergent variants with some such as the delta variant demonstrating significantly increased 
transmission (Ke, Romero-Severson et al. 2021).  Overall, the original outbreaks followed similar 
wave patterns of new confirmed cases that have been documented from the 1918 flu pandemic 
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with similar wave patterns occurring during similar seasonal time frames (He, Zhao et al. 2020). 
Similar epidemiological curves were present in nations with similar intervention responses and 
climate, as the United Kingdom’s winter wave peaked one day apart from the peak in the 
United States, further cementing the seasonality of the virus. However, recent emergence of 
variants of concern have been documented with increased transmissibility by as much as 40%, 
driving exponential increases in India and the United Kingdom (Davies, Abbott et al. 2021) . The 
dramatic increase in the United Kingdom is particularly alarming as currently the United 
Kingdom is one of the most vaccinated countries in the world, yet had increased new daily case 
counts per capita nearly 400% between May 22 and June 13. Furthermore, a similar spike was 
noticed in Israel, the most vaccinated western nation, increasing weekly confirmed cases from 
221 on the week of June 14 to 15,454 on the week of July 26, a 6992% increase in a little over a 
months’ time. However, it should be noted that deaths in vaccinated regions are significantly 
depressed compared to unvaccinated regions, and as cases in both countries climb, regions that 
have high vaccination rates are noticing very little increase in mortality compared to the nearly 
identical curves between cases and deaths in low vaccinated regions.  
Prior to the creation, production and emergency authorization of vaccines, the principal 
intervention was isolation of infected patients and quarantine of close contacts. This proved 
effective against SARS-CoV, ultimately leading to its full eradication, however the asymptomatic 
spread of SARS-CoV-2 as well as lack of public trust and adherence to protocols has limited the 
effectiveness of these strategies (Wilder-Smith 2020). Furthermore, several countries issued 
lockdowns and cordon sanitare, most notably China’s initial attempts to keep the virus within 
the city of Wuhan and the Hubei province, though lockdowns had varying effectiveness among 
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nations who implemented this strategy depending mostly on the compliance of the population 
to the lockdown rules. Countries such as China, Japan, and South Korea all instituted strict 
measures, and were able to decrease their rate of transmission or Rt by 4.78, 3.2, and 4.36 
respectively, compared to the United States which instituted mild control measures leading to 
only a 1.86 reduction in Rt 4 weeks after establishment of community transmission (Gu, Yan et 
al. 2020). Furthermore, countries who were slow to implement measures had significantly 
higher average Rt values compared to countries who took quick action at the establishment of 
community transmission (Gu, Yan et al. 2020).  However, nearly every nation instituted 
mandatory surgical mask requirements for those in public, with this intervention capable of 
decreasing R0 below 1.0,  the necessary threshold to stop an epidemic, if followed strictly by a 
large cohort of the population (Howard, Huang et al. 2021). Overall, these interventions, even 
in countries who were slow to adopt them, have directly saved millions of lives and were 
capable of controlling the virus within island nations such as New Zealand and Australia.   
 
1.3 Clinical Pathology of SARS-CoV-2 
 
Symptomatic SARS-CoV-2 infection has been summarized via the name Coronavirus Disease 
2019 (COVID-19). Severe COVID-19 has disproportionately affected men, especially those with 
significant comorbidities (Yanez, Weiss et al. 2020). Additionally, older age groups have been 
impacted by severe disease at significantly higher rates than younger people, with 65+ age 
group accounting for 46% of hospitalizations and having a 62x higher chance of mortality than 
those in the 55-64 age group (Yanez, Weiss et al. 2020). Furthermore, the 55-64 age group has 
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nearly 8x higher mortality rate than those younger than 55, and men in all age groups had 77% 
higher mortality compared to women (Yanez, Weiss et al. 2020). Moreover, minority 
populations have faced significantly higher rates of mortality with black and Latino populations 
having 3.5x and 1.88x the mortality of white counterparts, though this is likely due to societal 
factors such as minorities making up a larger proportion of essential employees, as well as poor 
access to healthcare, and mistrust of medical community (Gross, Essien et al. 2020). 
The course of the disease tends to follow similar courses to other viral respiratory infections 
with mild COVID-19 normally begins with a fever, dyspnea, and a persistent cough that is 
difficult to treat with over-the-counter medication. Additionally, diarrhea, fatigue, and myalgia 
are also common in mild cases, making it difficult to diagnose from other respiratory infections 
(He, Cheng et al. 2021). Normally symptoms will resolve within a week, however there have 
been increasing incidences of ‘long-covid’, where symptoms, especially fatigue and loss of 
olfactory senses, will persist for months following viral clearance by the immune system. This is 
believed to be caused by a number of factors including persistent immune system 
dysregulation, organ damage from the acute infection, as well as post-intensive care syndrome 
(Nalbandian, Sehgal et al. 2021). However, the majority of patients will recover in full with 
limited long-term effects of their acute viral infection. 
This is in stark contrast to severe COVID-19 patients who face significant organ damage 
brought on by cytokine storms, as well as significant mucosal damage to both the upper and 
lower respiratory tract leading to ‘ground glass’ lung CT scans and myocarditis in otherwise 
healthy individuals (Kong, Yang et al. 2020). Significant quantities of complement factors MBL, 
C3, and C5 among others have been found in immunohistochemistry staining in damaged lung 
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endothelial cells, as well as in alveolar spaces in damaged lung tissue (Noris, Benigni et al. 
2020). Additionally, inhibition of C5a has been shown in mouse models to significantly reduce 
leukocyte infiltration in tissue samples of MERS and SARS infected mice, suggesting 
complement pathway activation plays an active role in beta coronavirus lung endothelial 
pathogenesis (Noris, Benigni et al. 2020). Furthermore, patients have presented with 
neurological complications including strokes and psychosis brought on by dysregulated 
inflammation and clotting in the cranium due to acute viral infection. However, fatal COVID-19 
progresses into Acute Respiratory Distress Syndrome, necessitating full mechanical ventilation, 
as well as septicemia and shock leading to multiple organ failure (Shanmugam, Mohammed et 
al. 2020). Moreover, damaged vasculature associated with deposition of the complement 
membrane attack complex (MAC), as well as decrease in fibrinolysis, brought on by acute 
infection, has led to a significant portion of patients developing thrombosis, causing strokes, 
pulmonary embolisms, and myocardial infarctions in patients months after initial recovery 
(Price, McCabe et al. 2020). In conclusion it should be noted that clotting, runaway 
inflammation, cytokine storms, and multiple organ failure have all been linked to dysregulated 
complement activation, which has been demonstrated in SARS and MERS patients (Noris, 
Benigni et al. 2020).  
 
1.4 Overview of the Complement System in Response to Viral Infection 
  
Complement is a system of the innate immune response comprised of dozens of soluble 
proteins that together help to identify, and eliminate pathogens as well as initiate the host 
inflammatory response (Ricklin, Hajishengallis et al. 2010). In many ways the complement 
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system is the first line of defense for the host immune response, and its dysregulation or 
elimination can severely harm the host leading to significant long-term effects.  
The complement cascade is activated, as seen in figure 1, by 3 distinct mechanisms that 
converge at the cleavage of factor 3, leading to the development of the membrane attack 
complex (MAC). The classical pathway is initiated by bound IgG & IgM immune complexes, 
leading to the creation of C3 convertase through complement factor 2 and factor 4 cleavage by 
complement factor 1. On the other hand, the lectin pathway is initiated by mannose binding 
lectin binding sugars found commonly on pathogen surfaces, initiating cleavage of complement 
factor 2 and factor 4 through MASP proteins, creating the C3 convertase and activating the 
cascade. Finally, in the alternate pathway soluble C3b generated from the classical and lectin 
pathway, binds to complement factor b and cleaved by factor D producing a C3 convertase. The 
alternative pathway serves mainly to amplify the response generated from the classical and 
lectin pathways to generate a more robust immune response.   
In viral infection specifically, the complement cascade is normally initiated by bound IgG 
and IgM complexes before complement proteins C3b, C4, and C1q bind the viral surface, 
inhibiting its ability to bind host cellular structures for cellular entry. Additionally, these 
complement proteins serve to opsonize a viral particle, facilitating more efficient uptake and 
destruction by immune cells such as dendritic cells and macrophages (Spear, Hart et al. 2001). 
However, viruses have proven effective at circumventing complement mediated elimination, 
with some viruses capable of dysregulating complement activation causing significant 
inflammation and cellular damage (Stoermer and Morrison 2010).  
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For viral infection in COVID-19 complement can be both a savior and a menace, leading to 
effective viral clearance or severe clinical complications. In persons with fatal infections of 
SARS, another fatal beta-coronavirus, C5a was implicated in alveolar damage leading to fatal 
organ failure, where reduced levels of C5a were a predictor of potential recovery from ARDS 
(Wang, Xiao et al. 2015). Furthermore, inhibition of C5aR1 receptor reduced lung injury and 
myeloid cell derived inflammation in lung tissue suggesting the complement pathway is a 
critical driver of ARDS in  COVID-19 patients (Carvelli, Demaria et al. 2020). Moreover, another 
common complement activation fragment of all pathways, C3a, is a potent anaphylatoxin 
known for its ability to cause vasopermeability and leukocyte recruitment in the inflammatory 
process leading to severe disease pathogenesis when dysregulated.  However, it is suggested in 
murine models that clearance of viral particles is dependent on an effective and efficient 
complement activation, so it is likely that complete exclusion of the complement cascade would 
only serve to harm the patient as loss of C3 has been demonstrated to significantly diminish the 
priming of cytotoxic and helper T-cells in murine models (Dunkelberger and Song 2010). Taken 
together it is clear that proper functioning complement is crucial to an efficient immune 
response but dysregulation, specifically increased levels of anaphylatoxins C3a and C5a, can 








Figure 1 Simplified Overview of the Complement Cascade 
 
This diagram demonstrates the role of the complement system in innate immunity. Activation of any one pathway 
leads to the activation of C3 and C3 convertase, leading to the deposition of C3a and C3b, facilitating inflammatory 
responses and phagocytosis respectively. Furthermore, activation eventually leads to the deposition of C5a and 








2.0 Specific Aims 
 
 
2.1 Objective 1: Investigate the Relationship Between Complement Activation Levels and 
Disease Severity in ICU Patients Hospitalized in Allegheny County  
 
Hypothesis: increases in consumption of complement factors 3 and 5 will result in lower 
levels of these factors in more severe cases while complement activation product, C3a will 
significantly increase in patients with more severe disease.  
Experimental approach: The study is comprised of patients who were PCR confirmed 
positive that presented at the UPMC emergency department with acute COVID-19 symptoms 
and were admitted for care. Overall, there are 26 patients comprised of 16 males and 10 
females, whose serum was used for all specific aims of the study. Ages range from 41 to 95 and 
both Caucasian and African-American patients are represented in the data set. Utilizing Enzyme 
Linked Immunosorbent Assays (ELISAs), the levels of C3, C3a, and C5 levels of the patients will 
be determined from serum obtained during routine lab tests while hospitalized, with increased 
levels of all factors suggesting increased complement cascade activation and potentially 
increased inflammation and immune cell infiltration in endothelial tissue. By measuring C3, C3a 
and C5 we will be able to determine complement consumption and cascade activation as 
cleavage of C3 to C3a is an indicator of complement cascade activation, as is the presence of 
C5. Cross-referencing the determined complement level with known disease severity upon 
admission will determine if there is a relationship between complement activation levels and 




2.2 Objective 2: Investigate how comorbidities affect complement activation in severe COVID-
19 patients 
 
Hypothesis: Levels of complement activation will be affected by comorbidities of patients, 
specifically obesity, cardio-pulmonary conditions and autoimmune disorders. Complement 
levels are known to be affected by weight as well as chronic conditions, and this hypothesis 
aims to determine if different complement levels from different chronic conditions effects the 
level of complement activation and hence the consumption of C3, C5 and elevation of C3a.  
Experimental approach: Patient complement levels will be cross-referenced with known 
comorbidities of patients identified upon admission to determine if there is a relationship 
between complement activation levels and comorbidities. From the cohort, there were 17 
patients with hypertension and 22 with diabetes. Average BMI was 34 for men and 34.59 for 
women with 20 patients total classified as obese. For analysis, students t-test will be run for 
each category comparing C3, C3a, and C5 levels between comparison groups, though a higher 
number of patients may be required to achieve statistical significance(p≤0.05) for some groups. 
Furthermore, patients were divided by WHO ordinal score with scores above 7 being classified 
as severe cases, and a score of 10 indicating a fatal outcome. Overall, due to the small size of 
our cohort population there is limited statistical power of the analysis, though there were still 






2.3 Objective 3: Investigate the Relationship between complement activation levels and 
Antibody production in COVID-19 severity  
      
Hypothesis: Increased Complement activation will correlate with formation of immune 
complexes. Complement activation is caused by bound immunoglobulins and high levels of non-
neutralizing antibodies can hyperactivate complement leading to more severe disease 
progression.  
Experimental Approach: Utilizing antibody titer data from our group and the data I 
generated measuring C3, C3a, and C5 levels of severe COVID-19 patients were compared to the 
humoral response data. Correlation coefficients were calculated to determine any correlative 
effects between complement activation and antibody titers as IgG immune complexes are a 
known activator of the complement cascade (Karsten and Köhl 2012). Additionally, groups were 
split into the same disease severity as objectives 1&2 to determine if any correlation is related 












3.1 Selection of Study Participants 
 
Participants were selected from PCR positive COVID-19 patients at UPMC hospitals in 
Pittsburgh, Pennsylvania. Study participants agreed to allow leftover serum samples from 
normal medical procedures to be used in the study. Data on patients was taken by medical 
professionals within the UPMC system and compiled by CTSI. Study participants were split into 
2 groups as seen in table 1, intubated and non-intubated, following the WHO ordinal score 
scale as seen in figure 2.    
 
Table 1 Demographics of Study Cohort 
Demographic table of patients enrolled in the study who are confirmed PCR positive for SARS-CoV-2. Data is 
broken down by ICU admission status for differing demographic variables relating to the study. 
Demographic variable Non-Intubated patients (WHO 
score 4-6) 
Intubated Patients (WHO score 
7-9) 
Total 
Men 6 10 16 
Women 1 9 10 
Hypertensive 1 15 16 
Diabetes 1 10 11 
Obesity 2 18 20 
Over 65 5 6 11 







Figure 2 WHO Ordinal Scoring Scale 
 
Mild disease is shaded in green, moderate in yellow, severe in orange, and lethal disease in red (Marshall, Murthy 
et al. 2020). For our purposes, scores 4-6 will classify the less severe group with 7-9 in the more severe intubated 
group.  
 
3.2 Complement Protein ELISAs 
 
High Binding, clear, 96 well microplates (Corning) were coated with antibodies in carbonate-
bicarbonate buffer in a Styrofoam container at 4° C overnight. Plates were then washed using 
PBS-T buffer (0.05% tween-twenty in PBS) six times. Plates were then blocked with 150ul of 5% 
(w/v) bovine serum albumin (Sigma) for one hour at room temperature. The standard curve 
was then added using 2-fold serially diluted purified complement protein diluted in 1% (w/v) 
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bovine serum albumin (Sigma) for a total of 10 dilutions. Normal human serum (Complement 
Technology) and a blank of 1% (w/v) bovine serum albumin was added before the plate was 
incubated for 2 hours at room temperature. The plate was then washed 6 times with 1X PBS. 
Corresponding detection antibody was then added diluted in 1% (w/v) bovine serum albumin 
(Sigma) and left to incubate for 1 hour at room temperature. The plate was then washed 6 
times with 1X PBS. Horseradish peroxidase diluted in 1% (w/v) bovine serum albumin (Sigma) 
was then added to the plate and left to incubate at room temperature for 1 hour. The plate was 
then washed 6 times with 1X PBS before 50 ul of room temperature TMB was added to each 
well for 20 minutes at room temperature. After the 20 minutes expired 1M hydrochloric acid 
(HCl) was added to each well. The plate was then read at 450 nm using a SpectraMax Plus 
PC380 microplate spectrometer using SoftMax Pro Software (Molecular Devices). 
Concentrations were calculated using logarithmic regression from GraphPad Prism statistical 
software.  
 
3.3 Patient Serum Complement ELISA 
 
High binding, clear, 96 well plates (Corning) were coated with C3, C3a, or C5 capture 
antibodies diluted in carbonate bi-carbonate buffer and left covered at 4°C overnight. After 
being left overnight, plates were washed 6 times with 0.05% by volume tween twenty in 
Phosphate buffer saline (PBS) wash solution before being blocked with 5% (w/v) bovine serum 
albumin (BSA; Sigma) diluted in PBS and left for 1 hour at room temperature. Subsequently 
plates were washed with wash solution before patient serum samples 2 times serially diluted in 
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1% (w/v) BSA were added along with standard curves and positive and negative controls. Plates 
were then left for 2 hours at room temperature before being washed 6 times with wash 
solution. Corresponding detection antibody diluted in 1% BSA (w/v) was then added to the 
plate before being left 1 hour at room temperature. Following this incubation, the plate was 
washed 6 times with wash solution before horse-radish peroxidase diluted in 1% BSA(w/v) was 
added and left for 1 hour at room temperature. This was followed by another 6 times wash 
with wash solution before room temperature TMB was added and left for 20 minutes. This 
reaction was stopped after 20 minutes with 1M Hydrochloric acid, and the plate was read at 
450 nm using a SpectraMax Plus PC380 microplate spectrometer using SoftMax Pro Software 
(Molecular Devices). Concentrations were calculated using logarithmic regression from 














4.1 Objective One: Establishing a Relationship between Complement Activation and Disease 
Severity within ICU Patients 
 
4.1.1 Determining the effect of Complement Activation on Disease Severity on Admission to 
ICU and Disease Severity Peak During Hospitalization 
ELISAs were performed on the cohort to determine levels of C3, C3a, and C5 upon 
admission to the hospital and how this correlated with disease severity. All patient serum 
showed conversion of C3 to C3a as well as consumption of C5, which is to be expected of a 
patient with an acute viral infection. These concentrations were analyzed compared to a 
patient’s World Health Organization Ordinal Score, which can be seen in figure 2, to ensure all 
patients were scored with minimal bias when determining disease severity. As seen in Figures 3 
A and C, none of the complement factor proteins significant correlated with disease severity 
upon admission to the hospital. However, in other studies within our group there has been 
correlation between complement consumption levels and disease severity when the full scope 
of disease severity is taken into account and not just severely ill patients.  Overall, C3 
complement activation was not significantly (p=0.8231) correlated with disease severity upon 
admission. Furthermore, C3a concentration levels were not significantly correlated with disease 
severity (p=0.2293). Finally, C5 concentrations were not significant between disease severity 
groups (p=0.9008). It should be noted however, that due to the small sample size and narrow 
focus of disease severity there was limited statistical power in the data.  Furthermore, this data 
specifically looks at score upon admission, which is not indicative of the full disease progression 






Figure 3 Correlation of Complement Factor Levels and Ordinal Score on Admission 
 
WHO ordinal scale used as a standard weighting of disease severity. A) C3 complement levels, no significant 
correlation seen. B) C3a complement levels, weak but not significant correlation between disease score and C3a 
levels. C) C5 complement levels, no correlation seen between disease severity and complement levels. 
 
4.1.2 Determining the Relationship Between Complement Activation and Progression to more 
Severe Disease 
Due to complement being a critical intiator of pathways leading to adaptive immunity, and 
thus antibodies, it is possible that complement concentrations could effect the overall disease 
progression of patients. As seen in figure 4, the ratio of C3 and C3a weakly negatively correlates 
with the worst disease score of the patients during hospitalization while C3 and C5 alone don’t 
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correlate either way. Overall, consumption of C3 to C3a, and subsequent presence of C5, 
correlated with highest obtained disease severity, though not signficantly. It should be noted 
however, that this data only examines a narrow spectrum of disease and investigation into 
differences in mild and asymptomatic disease should be explored.  
 
 
Figure 4 Correlation of Complement Factor Levels and Worst Ordinal Score During Hospitalization 
 
ELISAs of patient sera were performed to gauge concentration levels. A) No correlation between C3 concentrations 
and WHO scores. B) Weak positive correlation between C3a and WHO scores but not statistically significant likely 
due to small sample size C) No correlation between C5 levels and WHO scores. D) Weak correlation between the 




4.2 Objective 2: Determining the Effects of Comorbidities on Complement Activation in 
Severe COVID-19 Patients 
  
4.2.1 Investigating the effect of Non-cardio Pulmonary Comorbidities on Complement 
Activation 
It has been well described that complement levels, and complement activation can be 
affected by comorbidities common in the American population, such as obesity. C3 and C5 have 
been shown to have increased concentrations in obese patients, potentially leading to higher 
levels of inflammatory disease (Pomeroy, Mitchell et al. 1997). This is seen in figure 5a&b, as C3 
and C3a moderately correlates with obesity levels, while in figure 5c C5 has weak non-
statistically significant correlations. This data demonstrates that obesity is correlated with 
higher levels of C3 and C3a among the cohort of hospitalized patients.  
Obesity also is linked to many chronic conditions, including diabetes, where the increased levels 
of pro-inflammatory cytokines, glycerol, and NEFA significantly increase insulin resistance in 
patients leading to the development of type II diabetes (Al-Goblan, Al-Alfi et al. 2014). 
Development of diabetes can then lead to dysregulated glucose levels in the body, with 
unregulated insulin levels causing spikes in blood glucose (Al-Goblan, Al-Alfi et al. 2014).  
Furthermore, high levels of glucose can inhibit C3 deposition on pathogen surfaces, suggesting  
unregulated diabetes could inhibit complement conversion from C3 to C3a (Hair, Echague et al. 
2012). As seen in figure 6 however, there was not a significant difference between complement 
factors of diabetic or non-diabetic patients, although for C3, C3a and C5, mean complement 
factor levles are higher in the non-diabetic group. Taken together the data from specific aim 2 
suggests that BMI is the main effector on complement activation levels with less severe 





Figure 5 Correlation of Complement Factors and BMI score by Disease Severity 
 
BMI is significantly correlated with C3 and C3a concentrations (Fig A&B). C) Weak positive correlation between 
complement and C5 concentrations with no statistical significance. D) No correlation between C3/C3a ratio and 
BMI. For all figures patients who were not intubated clustered towards the lower BMI levels. 
 





























Figure 6 Complement Factor Levels by Diabetic Status 
 
A) Slight increase in C3 concentrations in those with diabetes though no statistically significant difference. B) Sligh 
increase in C3a concentrations in those with diabetes though there is no statistically significant difference. C) slight 
increase in C5 concentrations in those with diabetes though there is no statistically significant difference.  
 
4.2.2 Complement Activation in relation to cardio-pulmonary comorbidities in severe COVID-
19 patients 
Hypertension and heart disease increase risk of severe disease in COVID-19 patients with an 
adjusted odds ratio of 2.36 for patients developing severe disease with cardiopulmonary 
disease (Yang, Zheng et al. 2020). As seen in figure 7, our data supports that patients with 
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hypertension are at a higher risk of severe disease, as hypertensive patients cluster towards 
more severe WHO Ordinal Scores upon admission. However, when investigated with 
complement there is no significant differecnce in complement levels among hypertensive 
patients and non-hypertensive patients though the small sample size could negatively affect 
statistical signficance. Furthermore, there were limited differences in COPD complement 




Figure 7 Correlation of Complement Factor Levels and Worst Ordinal Score While Hospitalized by Hypertensive 
Status 
 
A) There is no correlation between C3 and WHO score on admission. B) there is very weak correltion between C3a 
levels and WHO score on admission but it is not statisitically significant C) there is no correlation between C5 and 
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WHO score on admission. For all figures patients without hypertension cluster towards the lower WHO score on 
admission. 
4.3 Objective 3: Investigating the Relationship Between Complement Activation and the 
Adaptive Immune Response in Severe COVID-19 Patients 
 
4.3.1 Conversion ratios and the Adaptive Immune Response 
Complement can serve as an initiator of immune response and it has been documented that 
effective complement conversion is necessary for development of humoral immuntiy against 
pathogens (Dunkelberger and Song 2010). Furthermore, IgG immunity can create a feedback 
loop increasing complement activation and inflammation, while IgA is also capable of activating 
the complement cascade through Mannose-binding lection (Rizk, Maillard et al. 2019). This is 
supported by the data shown in COVID-19 patients in figure 8, as as higher ratios of IgG led to 
increased complement activation demonstrated by the lower levels of C3 compared to higher 
levels of C3a in the cohort as seen in figure 8, with less severe patients having higher IgA ratios 
and thus decreased C3 to C3a conversion compared to patients with immune responses 
producing higher ratios of IgG though the low number of patients is likely responsible for the 











C3 to C3a conversion vs Ab ratio

















Figure 8 Correlation of Complement Activation to Antibody Ratio by Disease Severity 
 
More severe patients cluster towards higher ratios of IgG to IgA and higher rates of C3 to C3a conversion indicated 
by a lower C3 to C3a ratio. The correlative data is not significant however.  
 
4.3.2 Effects of Complement and Antibody Concentrations on Disease Severity in Severe 
COVID-19 Patients  
Finally, the effects of complement, and anitbody concentrations were analyzed for the 
effects on disease severity. Antibody titers were also investigated to determine if there was a 
relationship between complement factor  concentrations and effective viral binding and 
neutralization from humoral immunity. As seen in figure 9a, there is a moderate, statistically 
significant, postive correlation between serum IgA concentrations and factor 3 levels. 
Furthermore, as seen in Figure 9b, IgA titers are weakly negatively correlated with C3a levels 
suggesting that higher IgA concentrations may be tied to C3 conversion to C3a in COVID-19 
patients, though this data was not statisticall significant. Taken together this suggsts that IgA 
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potentially inhibits consumption of C3 and production of C3a, and through complement down 
regultion potentially protects from more severe disease. However, as shown in  Figure 10 there 
is no significant correlation between complement C3, C5 and C3a with neutralization titers  
suggesting viral neutralization is not highly effected by complement in severe COVID-19 
patients. Finally, in Figure 11a , it is shown that anti-spike glycoprotien IgG significantly 
correlates with neutralization of SARS-CoV-2 virus comparative to both anti-nucleocapsid 
antibodies as well as anti-spike glycoprotein IgA, suggesting that the potentially protective 
effects seen in Figure 9 from IgA is likely not a result of IgA neutralizing SARS-CoV-2 but 
preventing excessive complement activation and inflammation. Overall, the data obtained 
suggests that IgA potentially down regulates complement activation, and IgA is not responsible 














Figure 9 Correlation of Complement Factors to IgA concentrations by Disease Severity 
 
Anti-Spike glycoprotein IgA demonstrated to have immuomodulating effects on complement cascade activation 
and conversion of C3 to C3a. A) C3 concentratons are moderately correlated with IgA concentrations. Additionally, 
less severe patients seem to cluster towards higher IgA levels. B) There is a weak negative correlation between C3a 



































Figure 10 Correlation of Complement Factors to PRNT Titers 
 
Complement concentrations in relation to in vitro plaque reduction neutralization test titers are non significant, 
suggesting that complement concentration is slightly correlated with viral neutralization. A, B, C, D) None of the 







Figure 11 Correlation of Antibodies to PRNT Titers by Disease Severity 
 
A) There is a moderately postive correaltion between anti-spike IgG and neutralization titers indicating that IgG is a 
driver of viral neutralization. B, C, D) there is no signficant correlation among Anti-Spike IgA or Anti-nucleocapsid 




































Overall, it has been demonstrated in the literature that complement activation has been a 
significant contributor to disease severity, primarily through recruitment of immune cells, and 
thus inflammatory molecules, into endothelial tissue (Java, Apicelli et al. 2020). Additionally, 
retroactive studies have demonstrated that obesity is a significant risk factor for severe disease 
progression with an adjusted risk ratio of 1.42 compared to healthy patients (Poly, Islam et al. 
2021). These factors taken with the data in figure 5a and 5b suggests that it is possible that 
increased complement activation associated with obesity is a contributor to worse disease 
progression among obese patients as seen in meta-analyses of COVID-19 patients.  
Apart from comorbidities, the adaptive immune response plays a critical role in regulation 
and activation of the complement cascade during viral infection. It has been well documented 
throughout the literature that bound immune complexes, specifically IgG and IgM activate the 
complement cascade through the classical complement pathway (Diebolder, Beurskens et al. 
2014). In contrast it has also been documented that bound IgA can inhibit activation of the 
classical complement pathway as a regulatory mechanism and thus reduce inflammation during 
viral infection (Russell, Reinholdt et al. 1989). The interplay between IgG activation and IgA 
regulation of complement activation in COVID-19 patients was weakly suggested in figure 8 as 
increased IgG serum level were weakly associated with increased activation though this data 
was not significant. However, when looking specifically at the regulatory effects of IgA there is 
significant positive correlation between serum IgA and factor 3 levels suggesting that the 
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regulatory function of bound serum IgA is potentially reducing complement activation in 
COVID-19 patients and thus potentially reducing the deleterious inflammatory response.  
Finally, it has been documented that serum IgG and IgA significantly correlates with viral 
neutralization in both severe and non-severe COVID-19 patients (Chen, Tong et al. 2020). In 
figure 11 it is demonstrated that serum IgG is associated with viral neutralization in our cohort 
of patients as well. Additionally, it is seen in figure 11 that IgA does not correlate with viral 
neutralization, possibly due to the limited scope of disease investigated in the study or the 
small number of study participants, though it is expected that serum IgA would contribute to 
viral neutralization.  
Together the data from this study suggests that there is a complex interplay between 
comorbidities and humoral immunity when it comes to complement activation in COVID-19 
patients. It is possible that conditions such as obesity have worse disease progressions due to 
their increased complement activation states, thus leading to greater inflammation and cellular 
recruitment in endothelial tissues. Furthermore, our data suggests that IgA is inhibiting 
complement activation in COVID-19 patients, potentially modulating severe inflammation 
caused by complement overactivation though further tissue studies should be pursued to gauge 
the true in vivo effects. Finally, the data from the PRNT assays suggested that serum IgA 
affected disease progression through means other than viral neutralization, though it is likely 
some neutralization by serum IgA occurs.  
Overall, the study faced limitations in the conclusions that were able to be drawn, 
specifically from the low number of participants and the narrow scope of disease severity 
investigated. Moving forward, tissue studies into lung endothelial infiltration should be done to 
35 
 
determine if increased levels of serum IgA modulate infiltration of immune cells as well as 
cellular complement deposition. Furthermore, widening the scope of disease studied may 
provide increased insight, and statistical power, to correlative relationships investigated in this 
study. Finally, the effects of new variants, principally the delta variant, should be investigated in 
relation to complement activation to determine how they may alter complement activation and 

















6.0 Significance to Public Health 
 
 
COVID-19 has continued to strain public health infrastructure on every inhabited region. 
Recent emeregence of variants demonstrating increased ability to cause severe disease among 
younger groups has caused rapid increases in hospitlizations in recent weeks in even highly 
vaccinated regions. Furthermore, vaccine hesitancy has allowed for the emeregence of new 
varaitns as well as unmitigated spread of SARS-CoV-2 throughout communities. Throughout 
this, it has become apparent that the ability of medical professionals to treat acute SARS-CoV-2 
infection is important to reduce mortality associated with acute infection. By understanding 
mechanisms that contribute to significant disease progression, it can be possible to develop 
novel theraputic approaches to decrease disease severity among the hospitalized portion of the 
population. Finally, should there be an emergence of another pandemic beta-coronavirus in the 
future, elucidation of disease causing pathways of beta-coronaviruses could significantly 
improve the collective public health response in treating severe disease before prophalytic 
measures are availible. Further study of complements role should get a larger sample size in 
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